A Boost for Femtech Innovation in Portugal

Portugal is set to host a pioneering competition in the femtech sector, an initiative designed to catalyze innovation at the intersection of artificial intelligence and women's health. This challenge, the first of its kind, targets startups and research labs, offering a unique platform to transform embryonic ideas and clinical questions into concrete, real-world AI solutions.

The initiative was launched by the scientific platform EmbryoNet-AI, in collaboration with FemTech Real Money Talks Media. Its primary goal is to accelerate breakthroughs in a field that, as highlighted by Elena Lipilina, co-founder and CMO of EmbryoNet-AI, has long been underfunded and under-researched. The competition aims to bring to light talented teams that are advancing this crucial sector.

Artificial Intelligence Serving Women's Health

The competition specifically targets clinical and drug discovery challenges where AI has the potential to make a significant impact on women's health. Areas of interest include projects leveraging time-series phenotyping to improve understanding of drug response and disease mechanisms, in fields such as gynecological cancers, endometriosis, and fertility research.

EmbryoNet-AI is also interested in teams proposing solutions to accelerate medical image pre-labelling, derived from mammography, pelvic MRI, ultrasound, or pathology slides. Another key focus involves solutions that combine phenotypic and clinical data to support decision-making in clinical trials, biomarker discovery, and treatment stratification. These approaches often require the processing of large volumes of data, implying the need for robust infrastructure for model inference and training.

The Competition Journey and Benefits for Winners

The selection process includes an initial open call, which will remain open until April 28, 2026. Interested teams, both Portuguese and international, must present a strong hypothesis and demonstrate access to relevant imaging or time-series data. From the submissions, organizers will select up to ten companies based on criteria such as potential impact on women's health, data readiness, alignment with EmbryoNet-AI's capabilities, feasibility within the program timeframe, the strength of their business case, and ethical and sustainability considerations.

Selected teams will advance to a Mentor Sprint, scheduled for early May 2026, where they will work closely with experts across technology, marketing, and clinical domains to refine their projects. The program will culminate in a Live Pitch Day, also in May 2026, during which finalists will present their solutions to a panel of investors and experts. The winning team will benefit from an 8-10 week build period, from May to July 2026, during which EmbryoNet-AI will deliver a fully developed, "services-first" pilot at no cost. This support translates into an estimated saving of €65,000 to €100,000, the typical cost for Minimum Viable Product (MVP) development, depending on product complexity.

Future Prospects and AI's Impact in the Sector

Beyond significant development support, the winner will gain direct access to investors active in women's health and AI-driven biotech. This also includes enhanced public credibility, thanks to investor-ready materials like pitch decks and targeted media exposure. Such opportunities are crucial for early-stage startups, which often struggle to secure funding and visibility.

This competition not only offers a launchpad for innovative solutions but also highlights the growing recognition of AI's transformative role in traditionally complex sectors like medicine. The emphasis on imaging and time-series data, combined with application to specific clinical problems, demonstrates how AI can be a powerful tool to address unmet medical needs, while also promoting data sovereignty and control over development processes, aspects increasingly relevant for organizations evaluating on-premise deployment of AI solutions.